… Anifrolumab, a human monoclonal antibody to type I interferon receptor subunit 1 investigated
for the treatment of systemic lupus erythematosus (SLE), did not have a significant effect …

… IIb RCT, which included open-label anifrolumab treatment for up to 3 years. The primary …
of anifrolumab. A secondary objective was to evaluate the immunogenicity of anifrolumab, and …

… In the absence of head-to-head trials, indirect treatment comparisons (ITCs) can provide … )
from anifrolumab trials – to compare the efficacy of anifrolumab and belimumab for adults with …

… The results have also raised the question of the clinical phenotype of patients who might
best respond to anifrolumab treatment. Existing data suggests that anifrolumab may be …

… Anifrolumab might lower disease activity without initiating GCs and reduce GC doses,
especially in patients who experience minor flares after LLDAS achievement. Keywords: …

… strengthen the evidence in favor of anifrolumab and conduct a meta-… Our findings show that
anifrolumab is safe in the treatment of … , anifrolumab may be generally safe in the treatment of …

… and safety of anifrolumab 300 mg in patients with active systemic lupus erythematosus (SLE…
Metaanalysis performed to determine treatment efficacy and safety outcomes of three RCTs (…

… At week 52, anifrolumab treatment groups demonstrated improvements over placebo across
… with systemic lupus erythematosus (SLE) receiving anifrolumab 300 mg, anifrolumab 1,000 …

… Anifrolumab in SLE … years, the type I interferon pathway has gained a central role in systemic
lupus erythematosus (SLE) pathogenesis, and it has become an important treatment target.…

… been globally approved for the treatment of SLE, and recently anifrolumab has been approved
by … In clinical trials, anifrolumab treatment has been associated with a reduction in disease …